Skip to main content

Find Clinical Trials

Home
Conditions
Relapsed or Refractory CD19+/BCMA+ Hematologic Malignancies

Clinical trial condition

Relapsed or Refractory CD19+/BCMA+ Hematologic Malignancies

Explore clinical trials studying Relapsed or Refractory CD19+/BCMA+ Hematologic Malignancies. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Relapsed or Refractory CD19+/BCMA+ Hematologic Malignancies trial results

Not Yet Recruiting

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

NCT07113496

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL), Blood Protein Disorders, Burkitt Lymphoma, +34 more
Locations: The First Affiliated Hospital with Nanjing Medical University Nanjing, Jiangsu, China

View Trial Details